Dublin-based startup, LUMA Vision, specialising in cardiac imaging, has successfully raised $12 million (€11 million) in a Series A funding round.
The investment was led by LSP, a Netherlands-based company operating through its LSP Health Economics Fund 2, along with the Atlantic Bridge University Fund from Ireland. Additionally, medtech entrepreneurs and Enterprise Ireland also participated in the funding round.
LUMA Vision, established by CEO Fionn Lahart and CTO Christoph Hennersperger in 2017, conducts significant development activities in both Dublin, Ireland, and Munich, Germany. The company’s innovative Verafeye technology has the capability to generate 4D data from within the heart.
The primary objective of this technology is to enhance the effectiveness and safety of atrial fibrillation (AFib) treatment worldwide.
The $12 million investment will be utilized by LUMA Vision to propel product development, conduct clinical trials, and make preparations for commercialising the system in the United States.
CEO Fionn Lahart expressed excitement about the funding, stating that it will enable the company to expand their team in Dublin and Munich, advance product development, and ultimately fulfill their mission of improving AFib treatment for patients.